Impact of obinutuzumab alone and in combination for follicular lymphoma

Although rituximab-based chemoimmunotherapy prolongs the survival of patients with follicular lymphoma (FL), this disease is considered incurable in most patients. Thus, new therapies are needed not only for those in the relapsed/refractory setting, but also for initial treatment. Obinutuzumab (G, G...

Descripción completa

Detalles Bibliográficos
Autores principales: Sarraf Yazdy, Maryam, Cheson, Bruce D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6467363/
https://www.ncbi.nlm.nih.gov/pubmed/31360086
http://dx.doi.org/10.2147/BLCTT.S114173

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6467363/
https://www.ncbi.nlm.nih.gov/pubmed/31360086
http://dx.doi.org/10.2147/BLCTT.S114173

Ejemplares similares